Cancer Therapy Holds Lucrative Potential for CAR T-Cell Therapy Application
Global CAR T-cell therapy market is projected to witness robust growth during the forecast period (2019-2026). Various innovations under CAR T-cell therapy as well as recent launches of different CAR T-cell therapy drugs in regional markets are further expected to drive the growth of market during the assessment period.
North America would remain the prominent region for CAR T-cell therapy market stakeholders owing to high product availability within the region. CAR T-cell therapy is majorly used in relapsed or refractory B-cell lymphoma and has been recently approved for acute lymphoblastic leukemia (ALL). Currently, CAR T-cell therapy is being evaluated for the treatment of indications such as multiple myeloma which indicates a positive growth outlook for market.
Find Out More about the Report Coverage
- Novartis AG
- Gilead Sciences Inc.
- Celgene Corporation
- bluebird bio, Inc.
Critical Need for Immunotherapy
With an alarming rate of increase in prevalence of cancers, the need for breakthrough therapeutic solutions such as CAR T-cell therapy continues to be critical. Recent studies suggest that over 1.7 million new cancer patients are recorded in the U.S. alone, and nearly 4.3 million in China.
Lymphoma and leukemia are particularly more prevalent. Reports project around 32,110 new cases of myeloma, 82,310 new cases of lymphoma, and 61,780 new cases of leukemia to be registered in the U.S. by 2019 end.
While these numbers seem to be intimidating, they also signal an opportunity for the growth of CAR T-cell therapy market. Chemotherapy and radiation are currently the only therapies available in most parts of the world. However, the introduction of immunotherapies is disrupting the entire perspective of cancer treatment.
CAR T-cell therapy is the latest immunotherapy type for cancer treatment, post success of the immune checkpoint inhibitors for cancer treatment.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
Eyeing Improved Efficacy of Cancer Treatment
CAR T-cell therapy is developed from the person’s own T-cells i.e. by using person’s own immune cells against cancer cells. This helps in targeting cancer cells more precisely underlining the novel nature of CAR T-cell therapy. CAR T-cell therapy is preferred in patients who have stopped responding to available treatment options. CAR T-cell therapy has also increased the rate of cancer remission.
CAR T-cell therapy is a single home infusion therapy devices and does not require frequent visits to the healthcare settings and improves patient compliance. Two marketed CAR T-cell therapy products are Kymriah (Novartis AG) and Yescarta (Gilead Sciences Inc.). These two products have showcased 83% and 72% rate of putting patient in remission, respectively, in case of B-cell non-Hodgkin lymphoma.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Academic Institutes Emerging as Research Organizations
The field of immuno-oncology is booming with billions of research & development funding for evaluation of new therapies. Growing partnership of academic institutes and private research centers with various pharmaceutical & biopharmaceutical companies is helping in clinical evaluation of various potential cancer therapies and also managing R&D expenditure.
Basic research continues to be prominently carried out at academic institutes & private research centers as companies focus on commercializing their products with an eye towards generating profits.
According to the National Science Foundation’s 2015 report, more than 50% of basic research conducted in the U.S. is carried out in academic institutes, whereas over 60% of all applied research and 87% of development of products is carried out in industries. CAR T-cell therapy is also developed by private cancer centers and is being launched in partnership with the biopharmaceutical company.
Novartis developed its CAR T-cell therapy (Kymriah) in collaboration with the University of Pennsylvania (Penn). Kymriah is first FDA approved CAR T-cell therapy for treatment of relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and B-cell acute lymphoblastic leukemia (ALL).
Explore Persistence Market Research’s expertise in promulgation of the business !
Receiving Orphan Drug Designation
Various clinical stage manufacturers received orphan drug designation by the Food and Drug Association (FDA) for their CAR T-cell therapy agent, which is further being evaluated for various cancer treatments.
- In July 2019 MB-102 (Mustang Bio) a CAR T-cell therapy agent received FDA orphan drug designation for treatment of acute myeloid leukemia. MB-102 is being co-developed by Mustang Bio along with City of Hope National Medical Center
- In September 2019, CT053 (CARsgen Therapeutics) received orphan drug designation for treatment of multiple myeloma
CAR T-cell therapy market growth is majorly driven by the product launches, expansion of manufacturing facilities in different region and extensive number of products in late stage of clinical development. Currently, Novartis AG and Gilead Sciences Inc. are the only players operating in the CAR T-cell therapy market.
Key players are prominently focusing on increasing their product availability in different countries and are specifically targeting treatment of Relapsed Large B-cell Lymphoma and ALL. Gradually increasing number of various regional, small & medium manufacturers clinically evaluating CAR T-cell therapy agents expected to crowd the market place over the forecast period.
Key Segments of CAR T-Cell Therapy Market
PMR’s study on the CAR T-cell therapy market offers information divided into four important segments-product, function, application, end user, and region. This report offers comprehensive data and information about the important market dynamics, and growth parameters associated with these categories.
Key Questions Answered in PMR’s CAR T-Cell Therapy Market Report
- Which regions will continue to remain the most profitable regional markets for CAR T-cell therapy market players?
- Which factors will essentially induce a change in the demand for CAR T-cell therapy in the forecast period?
- How will changing trends impact the CAR T-cell therapy market?
- What are key manufacturers’ strategy to enhance their product adoption and improve regional product footprints?
- Which companies are leading the CAR T-cell therapy market?
- What are the winning strategies of stakeholders in the CAR T-cell therapy market to upscale their position in this landscape?